Similar articles for PMID: 26719576

Year	Number of Results
2003	1
2007	1
2010	3
2011	7
2012	7
2013	11
2014	15
2015	18
2016	18
2017	19
2018	14
2019	19
2020	16
2021	19
2022	14
2023	1
2024	0

1

A Cyclin-Dependent Kinase Inhibitor, Dinaciclib, Impairs Homologous Recombination and Sensitizes Multiple Myeloma Cells to PARP Inhibition.

Alagpulinsa DA, Ayyadevara S, Yaccoby S, Shmookler Reis RJ. Alagpulinsa DA, et al. Mol Cancer Ther. 2016 Feb;15(2):241-50. doi: 10.1158/1535-7163.MCT-15-0660. Epub 2015 Dec 30. Mol Cancer Ther. 2016. PMID: 26719576 Free PMC article.

2

CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer.

Johnson SF, Cruz C, Greifenberg AK, Dust S, Stover DG, Chi D, Primack B, Cao S, Bernhardy AJ, Coulson R, Lazaro JB, Kochupurakkal B, Sun H, Unitt C, Moreau LA, Sarosiek KA, Scaltriti M, Juric D, Baselga J, Richardson AL, Rodig SJ, D'Andrea AD, Balmaña J, Johnson N, Geyer M, Serra V, Lim E, Shapiro GI. Johnson SF, et al. Cell Rep. 2016 Nov 22;17(9):2367-2381. doi: 10.1016/j.celrep.2016.10.077. Cell Rep. 2016. PMID: 27880910 Free PMC article.

3

Bortezomib-induced "BRCAness" sensitizes multiple myeloma cells to PARP inhibitors.

Neri P, Ren L, Gratton K, Stebner E, Johnson J, Klimowicz A, Duggan P, Tassone P, Mansoor A, Stewart DA, Lonial S, Boise LH, Bahlis NJ. Neri P, et al. Blood. 2011 Dec 8;118(24):6368-79. doi: 10.1182/blood-2011-06-363911. Epub 2011 Sep 13. Blood. 2011. PMID: 21917757 Free PMC article.

4

The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer.

Wilson AJ, Stubbs M, Liu P, Ruggeri B, Khabele D. Wilson AJ, et al. Gynecol Oncol. 2018 Jun;149(3):575-584. doi: 10.1016/j.ygyno.2018.03.049. Epub 2018 Mar 20. Gynecol Oncol. 2018. PMID: 29567272 Free PMC article.

5

Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer.

Carey JPW, Karakas C, Bui T, Chen X, Vijayaraghavan S, Zhao Y, Wang J, Mikule K, Litton JK, Hunt KK, Keyomarsi K. Carey JPW, et al. Cancer Res. 2018 Feb 1;78(3):742-757. doi: 10.1158/0008-5472.CAN-17-1494. Epub 2017 Nov 27. Cancer Res. 2018. PMID: 29180466 Free PMC article.

6

Protein expression of DNA damage repair proteins dictates response to topoisomerase and PARP inhibitors in triple-negative breast cancer.

Boerner JL, Nechiporchik N, Mueller KL, Polin L, Heilbrun L, Boerner SA, Zoratti GL, Stark K, LoRusso PM, Burger A. Boerner JL, et al. PLoS One. 2015 Mar 16;10(3):e0119614. doi: 10.1371/journal.pone.0119614. eCollection 2015. PLoS One. 2015. PMID: 25774912 Free PMC article.

7

Cyclin-dependent kinase inhibitor dinaciclib potently synergizes with cisplatin in preclinical models of ovarian cancer.

Chen XX, Xie FF, Zhu XJ, Lin F, Pan SS, Gong LH, Qiu JG, Zhang WJ, Jiang QW, Mei XL, Xue YQ, Qin WM, Shi Z, Yan XJ. Chen XX, et al. Oncotarget. 2015 Jun 20;6(17):14926-39. doi: 10.18632/oncotarget.3717. Oncotarget. 2015. PMID: 25962959 Free PMC article.

8

Dinaciclib, a Cyclin-Dependent Kinase Inhibitor Promotes Proteasomal Degradation of Mcl-1 and Enhances ABT-737-Mediated Cell Death in Malignant Human Glioma Cell Lines.

Jane EP, Premkumar DR, Cavaleri JM, Sutera PA, Rajasekar T, Pollack IF. Jane EP, et al. J Pharmacol Exp Ther. 2016 Feb;356(2):354-65. doi: 10.1124/jpet.115.230052. Epub 2015 Nov 19. J Pharmacol Exp Ther. 2016. PMID: 26585571 Free PMC article.

9

Ganetespib overcomes resistance to PARP inhibitors in breast cancer by targeting core proteins in the DNA repair machinery.

Jiang J, Lu Y, Li Z, Li L, Niu D, Xu W, Liu J, Fu L, Zhou Z, Gu Y, Xia F. Jiang J, et al. Invest New Drugs. 2017 Jun;35(3):251-259. doi: 10.1007/s10637-016-0424-x. Epub 2017 Jan 23. Invest New Drugs. 2017. PMID: 28111726

10

Identification of DNA repair pathways that affect the survival of ovarian cancer cells treated with a poly(ADP-ribose) polymerase inhibitor in a novel drug combination.

Huehls AM, Wagner JM, Huntoon CJ, Karnitz LM. Huehls AM, et al. Mol Pharmacol. 2012 Oct;82(4):767-76. doi: 10.1124/mol.112.080614. Epub 2012 Jul 25. Mol Pharmacol. 2012. PMID: 22833573 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

158 results

Results by year